M. avium Complex and Other Nontuberculous Mycobacteria and HIV
Mycobacterium avium Complex
Mycobacterium avium complex (MAC) comprises two closely related acid-fast bacteria, M. avium and M. intracellulare. The most common clinical presentation of disease due to these organisms in adults is infection of the respiratory tract, primarily seen in immunocompetent individuals with underlying chronic pulmonary disease, while disseminated infection is primarily a complication of advanced human immunodeficiency virus (HIV) infection. Although the incidence of disseminated MAC infection (dMAC) has declined significantly with the widespread use of potent combination antiretroviral therapy (ART), it still remains an important complication of advanced HIV infection.
Mycobacterium aviumcomplex organisms are thought to have little virulence in the normal host, and prior to the onset of the HIV epidemic had mostly been recognized as a cause of localized pneumonia in persons with chronic pulmonary disease. Reports of dMAC infection were...
KeywordsHuman Immunodeficiency Virus Acquire Immune Deficiency Syndrome Immune Reconstitution Inflammatory Syndrome Mycobacterium Avium Complex Primary Prophylaxis
- Benson CA, Williams PL, Currier JS, et al. A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome. Clin Infect Dis. 2003;37:1234–43.CrossRefPubMedGoogle Scholar
- Cohn DL, Fisher EJ, Peng GT, et al. A prospective randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients: excess mortality associated with high-dose clarithromycin. Terry Beirn Community Programs Clinical Research on AIDS. Clin Infect Dis. 1999;29:125–33.CrossRefPubMedGoogle Scholar
- Currier JS, Williams PL, Koletar SL, et al. Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy- induced increases in CD4+ cell count. A randomized, double-blind, placebo-controlled trial. AIDS Clinical Trials Group 362 Study Team. Ann Intern Med. 2000;133:493–503.CrossRefPubMedGoogle Scholar
- El-Sadr WM, Burman WJ, Grant LB, et al. Discontinuation of prophylaxis for Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med. 2000;342(15):1085–92.CrossRefPubMedGoogle Scholar
- Gordin FM, Horsburgh CR. Mycobacterium avium complex. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 6th ed. Philadelphia: Elsevier Churchill Livingstone; 2005. p. 2897–909.Google Scholar
- Ward TT, Rimland D, Kauffman C, et al. Randomized, open-label trial of azithromycin plus ethambutol vs. clarithromycin plus ethambutol as therapy for Mycobacterium avium complex bacteremia in patients with human immunodeficiency virus infection. Veterans Affairs HIV Research Consortium. Clin Infect Dis. 1998;27:1278–85.CrossRefPubMedGoogle Scholar